ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata

Alopecia areata (AA) is a common autoimmune disease affecting over 700,000 patients in the US and is driven by loss of immune privilege (IP) in the hair follicles and subsequent attack by IFNγ-secreting immune cells Farudodstat is a potent, oral DHODH …